Drugs / Pucotenlimab
Trials 66 · started per year
today
2
3
7
4
3
3
5
12
27
201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07356466 | May 2025 → Apr 2027 expected | gastric cancer | Fujian Medical University | Enrolling by invitation | No outcome recorded |
| Phase 15 trials | ||||||
| Phase 1 | NCT07054307 | Feb → Jul 2026 overdue | penile cancer | Jiyan Liu | Recruiting | No outcome recorded |
| Phase 1 | NCT05070221 | Oct 2021 → Oct 2023 | melanoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 1 | NCT05068453 | Oct 2021 → Oct 2023 | metastatic melanoma | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
| Phase 1 | NCT04756934 | Aug 2020 → Aug 2021 | melanoma | Taizhou HoudeAoke Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT04825392 | Sep 2019 → May 2021 | neoplasm | Taizhou Hanzhong Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/28 trials | ||||||
| Phase 1/2 | NCT07479485 | Apr 2026 → Apr 2028 expected | hepatocellular carcinoma | Lepu Biopharma Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07312422 | Sep 2025 → Apr 2026 overdue | malignant pancreatic neoplasm | Zhejiang Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06456892 | Jun 2024 → Jun 2026 overdue | childhood malignant neoplasm, rhabdomyosarcoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05338957 | Aug 2022 → Jun 2024 | cancer | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05688605 | Jun 2022 → May 2025 | cancer | Shanghai Miracogen Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04616443 | Dec 2020 → Nov 2025 overdue | melanoma | Binhui Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04750382 | Jul 2019 → Dec 2020 | triple-negative breast carcinoma | Taizhou Hanzhong Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03866525 | Apr 2019 → Aug 2025 overdue | digestive system cancer | Binhui Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 243 trials | ||||||
| Phase 2 | NCT07707167 | Aug 2026 → Jan 2028 expected | head and neck squamous cell carcinoma | Jiangsu Cancer Institute & Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07712029 | Aug 2026 → Aug 2028 expected | refractory malignant neoplasm | Tianjin Medical University Second Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07518979 | Jul 2026 → May 2028 expected | penile cancer | Jiyan Liu | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07692334 | Jul 2026 → Sep 2027 expected | gastric cancer, gastroesophageal junction adenocarcinoma | West China Second University Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07627321 | Jul 2026 → Jul 2028 expected | non-small cell lung carcinoma | Anhui Provincial Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07665190 | Jul 2026 → Oct 2027 expected | hypopharynx squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07649980 | Jul 2026 → Jul 2029 expected | biliary tract cancer | HuiKai Li | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07632339 | Jun 2026 → Jun 2028 expected | head and neck cancer | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Recruiting | No outcome recorded |
| Phase 2 | NCT07651007 | May 2026 → Dec 2027 expected | rectal cancer | Wang Xin | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07628855 | May 2026 → Aug 2028 expected | hereditary nonpolyposis colon cancer | Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07497919 | May 2026 → May 2029 expected | penile cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07501104 | May 2026 → Sep 2029 expected | melanoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07589049 | May 2026 → Nov 2027 expected | head and neck squamous cell carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07545083 | Apr 2026 → Mar 2027 expected | head and neck squamous cell carcinoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06889610 | Mar 2026 → Dec 2027 expected | colorectal cancer, melanoma, triple-negative breast carcinoma | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT07464366 | Mar 2026 → May 2028 expected | salivary gland carcinoma | Ji Dongmei | Recruiting | No outcome recorded |
| Phase 2 | NCT07514533 | Mar 2026 → Dec 2027 expected | cholangiocarcinoma | Sir Run Run Shaw Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07353827 | Feb 2026 → Aug 2027 expected | intrahepatic cholangiocarcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07381699 | Feb 2026 → Feb 2028 expected | nasopharyngeal carcinoma | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07393477 | Feb 2026 → Jul 2028 expected | head and neck squamous cell carcinoma | Sir Run Run Shaw Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07394244 | Jan 2026 → Dec 2028 expected | skin squamous cell carcinoma | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07354984 | Jan 2026 → Dec 2029 expected | head and neck squamous cell carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07353073 | Jan 2026 → Dec 2027 expected | mucosal melanoma | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06959108 | Oct 2025 → Jun 2029 expected | head and neck squamous cell carcinoma | Groupe Oncologie Radiotherapie Tete et Cou | Recruiting | No outcome recorded |
| Phase 2 | NCT07386158 | Jul 2025 → Dec 2026 expected | clear cell renal carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06969534 | May 2025 → Dec 2027 expected | carcinoma, lymphoepithelial-like carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT06895369 | May 2025 → Dec 2028 expected | head and neck squamous cell carcinoma | Sir Run Run Shaw Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07235566 | Apr 2025 → Apr 2029 expected | thyroid cancer | Fudan University | Recruiting | No outcome recorded |
| Phase 2 | NCT06872606 | Apr 2025 → Apr 2026 overdue | rectum adenocarcinoma | Sir Run Run Shaw Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06869174 | Mar 2025 → Mar 2027 expected | cancer of unknown primary site | Zhiguo Luo, MD, PhD | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06770270 | Aug 2024 → Dec 2027 expected | rectal cancer | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Phase 2 | NCT06530914 | Aug 2024 → Dec 2026 expected | head and neck squamous cell carcinoma | Lei Liu | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06524466 | Jul 2024 → Dec 2026 expected | hepatocellular carcinoma | Sun Yat-sen University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06192797 | Jun 2024 → Dec 2026 expected | intrahepatic cholangiocarcinoma | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06192784 | Dec 2023 → Jan 2025 | intrahepatic cholangiocarcinoma | Tongji Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06129955 | Nov 2023 → Dec 2025 | renal cell carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT04868162 | Apr 2021 → Jun 2026 overdue | head and neck squamous cell carcinoma | Shanghai Miracogen Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT04741165 | Jan 2021 → Apr 2022 | hepatocellular carcinoma | Taizhou Hanzhong Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04574817 | Dec 2020 → May 2022 | thyroid gland undifferentiated (anaplastic) carcinoma | Taizhou Hanzhong Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04738630 | Sep 2020 → Dec 2022 | urinary bladder cancer | Taizhou Hanzhong Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT04508803 | Sep 2020 → Aug 2022 | — | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT04749485 | Nov 2018 → Aug 2020 | melanoma | Taizhou Hanzhong Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT03704246 | Sep 2018 → Dec 2019 | neoplasm | Taizhou Hanzhong Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04750083 | Sep 2020 → Sep 2022 | non-small cell lung carcinoma | Taizhou Hanzhong Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 36 trials | ||||||
| Phase 3 | NCT07524413 | Apr 2026 → Apr 2030 expected | nasopharyngeal carcinoma | Sun Yat-sen University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07524452 | Feb 2026 → Feb 2031 expected | head and neck squamous cell carcinoma | Ming-Yuan Chen | Recruiting | No outcome recorded |
| Phase 3 | NCT06976190 | May 2025 → May 2029 expected | nasopharyngeal carcinoma | Shanghai Miracogen Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05652894 | Feb 2023 → Jun 2026 overdue | colorectal cancer | Taizhou Hanzhong Biomedical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05647954 | Dec 2022 → Dec 2024 | neuroendocrine neoplasm | Taizhou Hanzhong Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT04486651 | Sep 2020 → Aug 2023 | gastric cancer | Taizhou Hanzhong Biomedical Co., Ltd. | Unknown | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT07092449 | Aug 2025 → Dec 2027 expected | gastroesophageal adenocarcinoma, gastroesophageal junction adenocarcinoma | Tang-Du Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07188311 | Apr 2025 → Apr 2027 expected | childhood malignant neoplasm, hepatoblastoma | Sun Yat-sen University | Recruiting | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT07586124 Background | Jul 2026 → Dec 2027 expected | head and neck squamous cell carcinoma | Lepu Biopharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07448142 Background | Mar 2026 → Sep 2027 expected | colorectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07598318 Background | May 2026 → Dec 2027 expected | cholangiocarcinoma | Sir Run Run Shaw Hospital | Not yet recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07528209 Comparator | Apr 2026 → Apr 2032 expected | rectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 72 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pucotenlimab | “CONCLUSIONS: Pucotenlimab as a ≥ 2nd line therapy showed promising efficacy and tolerable toxicity for patients with locally advanced or metastatic melanoma.
TRIAL...” PMID 36747118 ↗ Feb 202351“We report a multicenter, phase 2 study evaluating the efficacy of pucotenlimab, an anti-PD-1 antibody, in patients with mismatch repair-deficient (dMMR) or microsatellite...” PMID 38016482 ↗ Nov 2023 “Neoadjuvant immunotherapy with pucotenlimab (200mg, Day 1, Q3W, 2 cycles); Adjuvant immunotherapy duiring and after radiotherapy with pucotenlimab (200mg, Day 1, Q3W, for a...” NCT07524452 ↗ “Multimodal ablation combined with pucotenlimab and TPC or sacituzumab govitecan, eribulin,gemcitabine,UTD1” NCT06889610 ↗ “short-course radiotherapy (SCRT) followed by NALIRIFOX chemotherapy plus Pucotenlimab immunotherapy” NCT07651007 ↗ “Pucotenlimab combined with chemotherapy (Nab-Paclitaxel + Tegafur + Carboplatin)” NCT07092449 ↗ “2. pucotenlimab： 200mg, intravenous, every 3 weeks, on day 1” NCT07514533 ↗ “[Docetaxel 75mg/m2 + Nimotuzumab 400mg + Pucotenlimab 200mg]” NCT07354984 ↗ “MRG006A+Pucotenlimab + Bevacizumab” NCT07479485 ↗ “Drug: HX008(Pucotenlimab)” NCT05652894 ↗ |
| Known as | HX008 | “Patients histologically confirmed mucosal melanoma will get OH2 （once every two weeks）and HX-008 (once every three weeks)and Axitinib (once every day).” NCT05070221 ↗22“Pucotenlimab (HX008): Administered from Cycle 1 to Cycle 4 at a dose of 3 mg/kg (maximum 200 mg), once every 3 weeks on Day 1 (D1).” NCT07627321 ↗ “Pucotenlimab (HX008) is a PD-1 inhibitor with an extended half-life (T1/2 = 21.76 days).” NCT07589049 ↗ “HX-008：200mg/time，Q3W，i.v.；” NCT05068453 ↗ “Pucotenlimab(HX008)” NCT07665190 ↗ |
| Known as | Puco | “After enrollment, patients will immediately begin treatment with Lenvatinib (Len) and Pucotenlimab (Puco).” NCT06524466 ↗ |
| Action | Inhibit | “PD-1 blockade monotherapy” NCT03704246 ↗ |
| Modality | Monoclonal antibody | “Anti-PD-1 Monoclonal Antibody” NCT04486651 ↗ |
| Route | Intravenous | “200 mg administered as IV infusion” NCT04486651 ↗ |
| Target | PDCD1 | “pucotenlimab, an anti-PD-1 antibody” PMID 38016482 ↗ Nov 2023 |